Compound Radar

ResMed Inc. (RMD) Stock Analysis

Price $221.05
Market cap $31.89B
Next earnings Oct 29, 2026
Entry status Watch $218.31–$228.35

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

76
76/100 Elite Quality
  • Financial Health 85
  • Profitability 75
  • Business Quality 75
  • Balance Sheet 65
  • Cash Flow 80

Why this rating?

Health 76/100 — Elite Quality

Strongest Financial Health 85/100
Softest Balance Sheet 65/100
Watch

Worth tracking, but timing is mixed — not a clear setup yet.

Company overview

ResMed Inc. (RMD) is a Medical Instruments & Supplies company in the Healthcare sector. Compound Radar rates ResMed Inc. 76/100 (Elite Quality) due to high business quality, steady revenue growth, and manageable leverage.

Investment profile

  • Quality High
  • Growth Moderate
  • Balance Sheet Adequate
  • Valuation Attractive

Financial highlights

Valuation

  • P/E 21.17
  • Forward P/E 16.73
  • PEG 1.33
  • EV/Revenue 5.71

Profitability

  • Revenue Growth 8.6%
  • Gross Margin 61.6%
  • Operating Margin 30.9%
  • Net Margin 26.9%
  • ROE 24.3%

Financial strength

  • Cash $1.47B
  • Debt $825.92M
  • Net Cash $643.32M
  • Free Cash Flow $1.63B
  • Current Ratio 3.1

Similar companies

Peers in Medical Instruments & Supplies, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Medical Instruments & Supplies →

FAQ

How Compound Radar scores and tracks ResMed Inc. (RMD).

View Methodology & FAQ →